SK Biopharmaceuticals announced on the 15th that Cenobamate, a new drug for epilepsy, has received marketing approval from the Canadian Department of Health. Cenobamate's commercialization in Canada is being handled by Paladin Labs, a local pharmaceutical company. Cenobamate is a new drug for epilepsy that SK Biopharmaceuticals is independently selling in the US. It was approved by the US FDA in 2019. Cenobamate was independently carried out by SK Biopharmaceuticals in the entire process from initial development to U.S. Food and Drug Administration (FDA) approval. It is prescribed for adult epileptic patients with partial seizure symptoms. It is a mechanism of action that relieves seizure symptoms by simultaneously regul